Prominent medical professionals participated in a scientific event organized by the American Academy of Pediatrics in collaboration with the Emirates Pediatric Society to present the latest advancements in influenza vaccination.

Dr. Entisar Al Hammadi, President of the Emirates Pediatric Society, explained that the newly introduced influenza vaccine stands out for its nasal spray delivery, replacing traditional needle injections. This innovation makes vaccination simpler, faster, and completely painless.
She noted that the vaccine is currently approved for individuals aged 2 to 49, while ongoing studies aim to expand its use to other age groups in the future. Dr. Ahmad Al Hammadi clarified that the current age limitation relates to weaker immune responses among the elderly, as the use of live attenuated viruses may occasionally trigger stronger symptoms compared to inactivated injectable vaccines.
She emphasized the importance of carefully balancing benefits and potential risks in all medical recommendations, and highlighted the need for annual vaccination due to the influenza virus’s tendency to mutate and change its form each season.





